On September 30, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab BPCIA litigation between Amgen, Inc. (“Amgen”) and ...

Amgen is rated between Hold and Buy with shares potentially slightly undervalued or fairly valued depending on FCF ...

Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab ...

Aug 13 (Reuters) - Amgen (AMGN.O), opens new tab has sued Samsung's biologics unit (207940.KS), opens new tab in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster ...

Historically known for its innovative biologic medicines such as Enbrel, Prolia and Repatha, Amgen AMGN has also emerged as ...

On October 4, 2024, Amgen filed a BPCIA complaint in the District Court for the Northern District of Illinois Eastern Division against Fresenius Kabi related to Fresenius Kabi’s proposed biosimilar of ...

Amgen beat Q1 estimates with EPS of $5.15 and revenues of $8.62B, both topping consensus. AMGN saw 16 drugs deliver double-digit growth, led by Repatha, Evenity and Uplizna. Amgen raised 2026 guidance ...

Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will permit it to market drugs in the United States that are biosimilars to Amgen's Prolia and Xgeva. Both medications use ...

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

AMGN is set to report Q4 results on Feb. 3, with consensus calling for sales of $9.46B and EPS of $4.74. Amgen's newer drugs and biosimilars may lift sales, but Prolia and Xgeva face erosion after U.S ...

Xgeva and Prolia are two drugs Amgen investors need to keep an eye on. Thanks to label expansion that permitted wider use of the drugs, they've been Amgen's fastest-growing products this past year.